Select Your Region
Americas
Europe
Africa
Global
How does the body process a cancer medicine (pralsetinib) – when it is taken together with another medicine (cyclosporine)
Cancer Cancer - RET positive
Basic Details
All
18 to 55 Years
Yes
Sponsor
F. Hoffmann-La Roche Ltd (Switzerland)
Phase
Phase 1
Study Identifier
GP43162
Fifteen healthy volunteers were enrolled at one study site in USA to evaluate the effect of coadministration of cyclosporine on the pharmacokinetics of pralsetinib in healthy males and females of non-childbearing potential. Thirteen participants completed the study. Results showed that coadministration of cyclosporine and pralsetinib increased exposure to pralsetinib and increased the highest concentration of pralsetinib reached post-dosing. There were no deaths or serious side effects. The data from this study will help support further development of pralsetinib.
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
What you can do next
To find this study again later, copy and save the study number:
{{ctId}}
Interested in more than one study? Log in to your ForPatients account to bookmark studies and get updates.
To see if this study is a good fit, talk to your doctor or nurse you trust.
Together, you can look at the For Medical Professional tab and look into your medical history.
Some medical centers in this study offer a contact line. Click "Find participating medical centers" in the map below.
For the latest version of this information please go to www.forpatients.roche.com